Palatin Technologies (NYSE:PTN) reported its fiscal second-quarter 2026 results on Tuesday, marking a critical operational pivot as the biopharmaceutical firm clears financial hurdles and prepares to enter the highly competitive clinical landscape for weight-loss therapies.
NeoGenomics (NASDAQ:NEO) delivered solid fourth-quarter 2025 results, with consolidated revenue increasing 11% year over year to $190 million, driven by robust demand for its oncology-focused diagnostic testing services.
IDEAYA Biosciences (NASDAQ:IDYA) reported fourth-quarter and full-year 2025 results on Tuesday, setting a definitive timeline for a high-stakes clinical readout that could transition the precision medicine firm into a commercial-stage biotech.
Eli Lilly (NYSE:LLY) announced Monday that its drug Retevmo reached the primary goal of a late-stage study, significantly improving event-free survival for patients with a specific genetic form of early-stage lung cancer.
Citius Oncology (NASDAQ:CTOR) officially transitioned from a development-stage clinical trial outfit to a revenue-generating commercial entity this quarter, posting its first sales of the newly approved immunotherapy LYMPHIR.
Helus Pharma (NASDAQ:HELP) reported financial results and clinical progress for the third quarter of fiscal 2026 ended December 31, 2025, highlighting a solid cash position and advancing late-stage programs targeting major psychiatric indications.
Beyond Air (NASDAQ:XAIR) reported a surge in third-quarter revenue and a strategic pivot toward its core respiratory business, announcing a binding agreement to divest its autism and neuro-oncology subsidiary to XTL Biopharmaceuticals.
Moderna (NASDAQ:MRNA) reported a massive full-year loss and revealed a significant regulatory setback in the U.S., as the Food and Drug Administration refused to review its experimental flu vaccine, complicating the biotech’s path to profitability.
West Pharmaceutical Services (NYSE:WST) shares gained momentum Thursday after the injectable-solution leader posted a fourth-quarter earnings beat and provided a bullish 2026 outlook, fueled by the explosive growth of GLP-1 "obesity" drugs and a massive jump in free cash flow.
Agios Pharmaceuticals (NASDAQ:AGIO) today released financial results and business updates for the fourth quarter and full year ended December 31, 2025, highlighting regulatory progress and commercial momentum in rare blood disorders.
Upstream Bio (NASDAQ:UPB) announced breakthrough results for its lead candidate, verekitug, in a mid-stage trial that could disrupt the multibillion-dollar biologics market for severe respiratory diseases.
Veru (NASDAQ:VERU) reported a significantly narrowed operating loss for the first fiscal quarter, as the biopharmaceutical firm pivots its resources toward a high-stakes clinical trial for its muscle-preserving obesity treatment.
